AMGN – Amgen Inc.
Float Short %
2.79
Margin Of Safety %
Put/Call OI Ratio
0.6
EPS Next Q Diff
-0.81
EPS Last/This Y
13.63
EPS This/Next Y
0.8
Price
347.11
Target Price
336.96
Analyst Recom
2.24
Performance Q
15.25
Relative Volume
1.08
Beta
0.46
Ticker: AMGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | AMGN | 332.89 | 0.79 | 0.45 | 124590 |
| 2025-12-29 | AMGN | 329.64 | 0.80 | 2.33 | 119095 |
| 2025-12-30 | AMGN | 328.58 | 0.81 | 0.79 | 121930 |
| 2025-12-31 | AMGN | 327.33 | 0.81 | 0.51 | 123007 |
| 2026-01-02 | AMGN | 327.28 | 0.81 | 0.69 | 124531 |
| 2026-01-05 | AMGN | 320.7 | 0.83 | 0.54 | 126727 |
| 2026-01-06 | AMGN | 330.08 | 0.83 | 0.78 | 129757 |
| 2026-01-07 | AMGN | 341.58 | 0.85 | 0.41 | 133523 |
| 2026-01-08 | AMGN | 330.09 | 0.80 | 1.56 | 148470 |
| 2026-01-09 | AMGN | 326.12 | 0.78 | 0.94 | 151536 |
| 2026-01-12 | AMGN | 325.48 | 0.79 | 2.31 | 150672 |
| 2026-01-13 | AMGN | 324.42 | 0.78 | 0.89 | 152835 |
| 2026-01-14 | AMGN | 329.02 | 0.79 | 0.47 | 153827 |
| 2026-01-15 | AMGN | 330.09 | 0.78 | 0.34 | 155987 |
| 2026-01-16 | AMGN | 330.47 | 0.76 | 0.39 | 158691 |
| 2026-01-20 | AMGN | 331.13 | 0.58 | 0.99 | 99485 |
| 2026-01-21 | AMGN | 343.6 | 0.61 | 0.50 | 104308 |
| 2026-01-22 | AMGN | 347.13 | 0.60 | 0.65 | 108809 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | AMGN | 332.87 | -10.7 | 4946.3 | 21.25 |
| 2025-12-29 | AMGN | 329.64 | -10.7 | 4861.4 | 21.25 |
| 2025-12-30 | AMGN | 328.70 | -10.7 | 4951.9 | 21.25 |
| 2025-12-31 | AMGN | 327.35 | -10.7 | 4936.1 | 21.25 |
| 2026-01-02 | AMGN | 327.83 | -10.7 | 5008.7 | 21.25 |
| 2026-01-05 | AMGN | 320.70 | -10.7 | 4717.0 | 21.25 |
| 2026-01-06 | AMGN | 330.34 | -10.7 | 5370.8 | 21.25 |
| 2026-01-07 | AMGN | 341.66 | -10.7 | 5434.6 | 21.25 |
| 2026-01-08 | AMGN | 330.05 | -10.6 | 4550.3 | 21.25 |
| 2026-01-09 | AMGN | 326.05 | -10.6 | 4830.5 | 21.25 |
| 2026-01-12 | AMGN | 325.56 | -10.6 | 4967.1 | 21.25 |
| 2026-01-13 | AMGN | 324.34 | -10.6 | 4941.3 | 21.25 |
| 2026-01-14 | AMGN | 328.92 | -10.2 | 5170.6 | 21.25 |
| 2026-01-15 | AMGN | 330.12 | -10.2 | 5033.3 | 21.25 |
| 2026-01-16 | AMGN | 330.41 | -10.2 | 5003.0 | 21.25 |
| 2026-01-20 | AMGN | 331.07 | -10.2 | 5014.0 | 21.25 |
| 2026-01-21 | AMGN | 343.66 | -10.2 | 5479.1 | 21.25 |
| 2026-01-22 | AMGN | 347.11 | -10.2 | 5120.3 | 21.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-29 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-30 | AMGN | -1.18 | -0.56 | 2.63 |
| 2025-12-31 | AMGN | -1.18 | -0.56 | 2.63 |
| 2026-01-02 | AMGN | -1.18 | -0.56 | 2.63 |
| 2026-01-05 | AMGN | -1.18 | -0.55 | 2.63 |
| 2026-01-06 | AMGN | -1.18 | -0.55 | 2.63 |
| 2026-01-07 | AMGN | -1.18 | -0.55 | 2.63 |
| 2026-01-08 | AMGN | -1.18 | -0.55 | 2.63 |
| 2026-01-09 | AMGN | -1.18 | -0.55 | 2.63 |
| 2026-01-12 | AMGN | -1.16 | -0.65 | 2.63 |
| 2026-01-13 | AMGN | -1.18 | -0.65 | 2.79 |
| 2026-01-14 | AMGN | -1.18 | -0.65 | 2.79 |
| 2026-01-15 | AMGN | -1.18 | -0.65 | 2.79 |
| 2026-01-16 | AMGN | -1.18 | -0.65 | 2.79 |
| 2026-01-20 | AMGN | -1.18 | -0.70 | 2.79 |
| 2026-01-21 | AMGN | -1.18 | -0.70 | 2.79 |
| 2026-01-22 | AMGN | -1.18 | -0.70 | 2.79 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.93
Avg. EPS Est. Current Quarter
4.74
Avg. EPS Est. Next Quarter
5.12
Insider Transactions
-1.18
Institutional Transactions
-0.7
Beta
0.46
Average Sales Estimate Current Quarter
9455
Average Sales Estimate Next Quarter
8637
Fair Value
346.88
Quality Score
86
Growth Score
90
Sentiment Score
98
Actual DrawDown %
-0.1
Max Drawdown 5-Year %
-24.9
Target Price
336.96
P/E
26.83
Forward P/E
15.75
PEG
3.18
P/S
5.21
P/B
19.43
P/Free Cash Flow
16.2
EPS
12.94
Average EPS Est. Cur. Y
21.25
EPS Next Y. (Est.)
22.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
19.52
Relative Volume
1.08
Return on Equity vs Sector %
45.6
Return on Equity vs Industry %
36.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
5120.3
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading